Find Academic Supervisors

• Tissue Engineering
• Biofabrication
• Cartilage Regeneration
• +3 more

Prof. Marcy Zenobi-Wong is a Full Professor at ETH Zurich's Department of Health Sciences and Technology, specializing in biofabrication and tissue engineering. Her research focuses on cartilage regeneration using advanced biomaterials, including nanofilm coatings and 3D printing techniques. She holds patents in tissue engineering and has pioneered methods like filamented light (FLight) biofabrication for creating anisotropic tissues. Her academic journey includes a B.Sc. from MIT (1985), M.Sc. and Ph.D. from Stanford (1987, 1990), followed by postdoctoral work at the University of Michigan. She leads the Biofabrication Group at ETH, developing therapies for joint repair and regenerative medicine. Courses taught include Biomedical Engineering and Materials and Mechanics in Medicine . Research highlights include engineered hydrogels for cartilage protection, CRISPR-driven gene editing in chondrocytes, and biohybrid neural interfaces. Her work bridges material science, cell biology, and clinical applications, with a focus on translational medicine. Collaborative projects involve creating elastic cartilage grafts for microtia reconstruction and volumetric printing of complex tissue constructs.

Andrew HolleView profile

Assistant Professor

• Mechanobiology
• Stem Cell Differentiation
• Cancer Mechanobiology
• +3 more

Andrew Holle is an Assistant Professor at the Mechanobiology Institute , National University of Singapore , where he leads the Confinement Mechanobiology Lab within the Department of Biomedical Engineering . His work spans mechanobiology, stem cell differentiation, cancer mechanobiology, and microfluidics, with a focus on understanding how physical confinement influences cellular behavior. Education: B.S.E. in Bioengineering (Minor in Statistics), Arizona State University (2008) Ph.D. in Bioengineering, University of California San Diego (2013) Research in the Confinement Mechanobiology Lab centers on the hypothesis that stem cell differentiation is driven by mechanical cues during migration through confined extracellular matrix (ECM) environments. The lab develops microfluidic systems to mimic ECM confinement and studies its impact on osteogenic differentiation , cancer cell migration , and cellular condensates . Recent publications highlight interdisciplinary approaches combining mechanobiology , nanotechnology , and microfluidics to explore nuclear morphological changes, volume regulation, and ligand signaling in confined cellular environments. Laboratory Members: Privita Edwina (Research Fellow) Vaishnavi Rangaraj (Research Assistant) Sriram Muthukumar (Research Fellow) Chang Ye Ji (PhD Student) Gao Xu (PhD Student) Lim Yuan Bin (PhD Student) Shinny Sunny (PhD Student) Lee Jia Wen Nicole (PhD Student) Li Yixuan (PhD Student)

Vivek ShenoyView profile

Professor

• Mechanobiology
• Multiscale Modeling
• Biomaterials
• +6 more

Vivek Shenoy is the Eduardo D. Glandt President's Distinguished Professor at the University of Pennsylvania, with primary appointments in the Department of Materials Science and Engineering and secondary appointments in Bioengineering and Mechanical Engineering and Applied Mechanics. He leads the Multiscale Mechanobiology and Biomaterials Laboratory, which focuses on developing theoretical frameworks and numerical methods to understand complex biological and engineering systems across multiple length scales. Shenoy's research spans mechanobiology, chromatin organization, cell mechanics, and biomaterials. His work addresses the fundamental challenge of modeling how small-scale cellular phenomena couple with long-range tissue-level interactions across micrometers to centimeters. By integrating insights from soft matter physics, solid mechanics, chemistry, and applied mathematics, his group develops multiphysics continuum and mesoscale theories to elucidate mechanisms controlling both biological and engineering systems. His recent publications demonstrate an increasing focus on nuclear mechanics, chromatin organization, and the interplay between mechanical forces and gene regulation. Analysis of Shenoy's publication record reveals a strong interdisciplinary approach, with high-impact papers spanning biophysics, materials science, and cell biology. His work shows consistent evolution from fundamental mechanics of materials to complex biological systems, with recent emphasis on the mechanical regulation of chromatin architecture, cell migration dynamics in 3D environments, and mechanotransduction in development and disease. His publications appear regularly in top journals including Nature, Science, and their affiliated publications, demonstrating significant influence across multiple fields. Eduardo D. Glandt President's Distinguished Professor Multiple publications in Nature, Science, and PNAS Active research program with publications through 2025 Shenoy actively mentors students and postdocs through his laboratory, with numerous co-authored publications indicating strong mentorship. His research program appears to be well-funded through multiple grants supporting his work in mechanobiology and biomaterials. The Multiscale Mechanobiology and Biomaterials Laboratory maintains active collaborations across disciplines and institutions, reflecting the interdisciplinary nature of his research. The Multiscale Mechanobiology and Biomaterials Laboratory, housed within the Department of Materials Science and Engineering at the University of Pennsylvania, serves as the primary research hub for Shenoy's work. The lab maintains an active presence on social media (Twitter: @ShenoyLab) for updates on activities and publications. Their research approach combines theoretical modeling with experimental validation to address fundamental questions at the interface of mechanics, materials science, and biology.

Andre LevchenkoView profile

Professor

• Systems Biology
• Signal Transduction
• Cell Communication
• +5 more

Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +7 more

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Rainer HaagView profile

Professor

• Biodegradable Materials
• Sustainable Polymer Chemistry
• Dynamic Hydrogels
• +7 more

Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.

Kelly ArnoldView profile

Associate Professor

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +5 more

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

Weiqiang ChenView profile

Professor

• Lab-on-a-Chip
• Organ-on-Chip
• Biomaterials
• +7 more

Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.

Matthias MannView profile

Professor

• Mass Spectrometry
• Proteomics
• Systems Biology
• +6 more

Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.

• Nanomedicine
• Therapeutic Targeting
• Drug Delivery Systems
• +4 more

Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)

• Stem Cell Mechanobiology
• Bone Tissue Engineering
• Regenerative Medicine
• +3 more

Chao Liu is an Associate Professor at the Department of Biomedical Engineering , Southern University of Science and Technology (2024.11–present). Previously, he served as an Assistant Professor at the same institution (2019–2024.11) and completed a Postdoctoral Fellowship at New York University (2016–2019) with joint appointments in the Department of Biomedical Engineering and Orthopedics at NYU Langone Health . He holds a PhD in Biomedical Engineering (2016) and MASc in Mechanical Engineering (2010) from University of Toronto , following a BASc in Engineering Science (2008). Education : PhD (IBBME, U of Toronto, 2016), MASc (Mechanical Engineering, U of Toronto, 2010), BASc (Engineering Science, U of Toronto, 2008) His research focuses on mechanobiology of stem cells , bone tissue engineering , and functional implants . He investigates how mechanical forces modulate osteogenic and angiogenic stem cells, designs implants with micro-geometry to enhance cellular activity, and develops 3D real-time imaging modalities for bone repair processes. His work spans biomechanics , regenerative medicine , and cellular mechanotransduction . The selected publications from 2022 to 2010 reveal trends in mechanical force applications for bone regeneration, pharmacological impairments in healing, nanostructured biomaterials for stem cell differentiation, and microfluidic platforms for osteocyte studies. These works are published in journals like Bone , FASEB Journal , and ACS Applied Materials & Interfaces . Scientific Awards : International Conference BME Young Investigator Award (2019), IFMRS Travel Grant (2017), ASBMR Young Investigator Grant (2016), CIHR Travel Awards (2010–2014), Ontario Graduate Scholarship (2011–2013), Barbara and Frank Milligan Fellowship (2008, 2010) Chao Liu mentors graduate students, including Zhang Jianing (2022 Master’s graduate). His lab ( https://abtrl.bme.sustech.edu.cn/ ) recruits postdocs and research assistants for projects in mechanical force applications , micro-geometric implants , and 3D imaging . He has contributed to 14 journal articles with 714 citations and presented at 6 international conferences in the past three years.

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +12 more

Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.

John A. Copland, IIIView profile

Professor

• Cancer Biology
• Molecular Carcinogenesis
• Translational Research
• +3 more

Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models

• Cellular Biophysics
• Materials Science
• Cell Biology
• +3 more

Prof. Joachim Spatz is a Full Professor of Biophysical Chemistry at Heidelberg University and Director of the Max Planck Institute for Medical Research. His academic career includes roles as Director at MPI for Metals Research (2004–2015) and Founding Director of the Institute for Molecular Systems Engineering (IMSE). He holds a PhD from Ulm University and habilitation in Physics, with postdoctoral training at the Institut Curie, Paris. His research spans cellular biophysics, materials science, and synthetic biology, focusing on mechanotransduction, cell-material interactions, and engineered biological systems. Education: 1989–1994: Dipl. Phys. (Physics), Ulm University & Colorado State University 1994–1996: PhD (summa cum laude), Ulm University 2000: Habilitation in Physics, Ulm University Research Interests: Spatz’s work integrates biophysics, materials science, and engineering to study cellular mechanics, synthetic cells, and mechanosensing. Key projects include developing synthetic cell models using microfluidics and exploring how mechanical forces regulate cell behavior in health and disease. Awards: 2017 Gottfried Wilhelm Leibniz Prize 2012 ERC Advanced Grant (with Prof. B. Geiger) 2002 Alfried Krupp Research Award Labs & Collaborations: Leads the Cellular Biophysics Department at MPI for Medical Research and collaborates with institutions like the Weizmann Institute and Jackson Laboratory. Active in interdisciplinary initiatives such as the Max Planck School Matter to Life.

• Sports Medicine
• Physiology
• Sports Injury
• +4 more

Michael Kjær is a Clinical Professor at the Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences. He specializes in Internal Medicine: Rheumatology and leads research groups focused on exercise physiology, sports injuries, and aging. His work addresses the impact of physical activity on the human organism, with particular emphasis on tissue damage and repair mechanisms. Dr. Kjær's primary research interests center around sports medicine, physiology, and exercise science. His work investigates tendon pathology, muscle physiology, sports injuries, and the effects of exercise on aging populations. He has made significant contributions to understanding sports-related injuries, particularly tendon overuse conditions, and the physiological responses to physical activity across different age groups. His recent publications (2025) demonstrate a strong focus on tendon research, sports injury treatment dilemmas, effects of anabolic steroid abuse, muscle physiology, and bone health in athletes and older adults. The research spans from basic science investigations of cellular mechanisms to clinical studies addressing practical sports medicine challenges. His work shows particular strength in connecting molecular and tissue-level changes with clinical outcomes in sports medicine. With 415 research outputs including 369 journal articles, 15 book chapters, and 15 reviews, Dr. Kjær maintains an active research program with substantial impact. His work has been referenced in Wikipedia pages, cited by Bluesky users, and picked up by news outlets, demonstrating its relevance to both academic and public discourse. Dr. Kjær leads multiple research groups within the Center for Healthy Aging Damage and Repair at the Department of Clinical Medicine. His laboratory work focuses on tissue response to injury and exercise, particularly examining tendon and muscle physiology using both in vivo and in vitro approaches. His research bridges basic science with clinical applications in sports medicine and rehabilitation.